Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or
Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy
Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell
lymphoma in China (Chidamide,a novel histone deacetylase inhibitor). Tirelizumab,has been
approved for the failure treatment of platinum-containing chemotherapy with high PD-L1
expression included locally advanced or metastatic Urothelial carcinoma in
China(Tirelizumab,BGB-A317 is an investigational humanized IgG4 anti-PD-1 monoclonal antibody
).The aim of this study was to observe the efficacy and safety of Chidamide with
Immunotherapy in patients with progression of platinum-based chemotherapy recurrent and
metastatic Urothelial carcinoma.
Metastatic Bladder Cancer,
Metastatic Bladder Carcinoma,
Bladder Cancer Stage IV
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.